
Intranasal Vaccine Brain Risk: The 2026 BPL-1357 Policy Playing Out
The scientific case for pausing NIAID's intranasal whole-virus platforms: direct olfactory-nerve access to the brain, full structural proteins …

The scientific case for pausing NIAID's intranasal whole-virus platforms: direct olfactory-nerve access to the brain, full structural proteins …
The median 18-day gap from COVID symptom onset to death in nursing homes points to secondary bacterial pneumonia a treatable condition often …

An examination of various viewpoints and data related to the COVID-19 pandemic, focusing on scientific studies, public health policies, and reported …